Milrinone Carinopharm

Milrinone, the active ingredient in Milrinone Carinopharm, is a phosphodiesterase 3 inhibitor presented as an intravenous solution for injection use. It provides positive inotropic support and vasodilation, and is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients requiring rapid hemodynamic improvement.

GNH USA supplies Milrinone Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, with established cold‑chain logistics and regulatory support. The product meets EU quality standards and is distributed under strict quality assurance protocols.

Milrinone is a phosphodiesterase‑3 inhibitor used in acute cardiac care. - Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid inotropic support and vasodilation to stabilize blood pressure. - Low cardiac output after cardiac surgery: enhances myocardial contractility to aid hemodynamic recovery.

Milrinone may cause a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: reduction in systemic blood pressure. - Headache: mild to moderate intensity. - Arrhythmia: premature ventricular or atrial beats. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe arrhythmias: ventricular tachycardia or fibrillation. - Myocardial ischemia: chest pain or ECG changes. - Severe hypotension: profound drop in blood pressure requiring intervention.

Milrinone requires careful monitoring and specific clinical considerations. - Monitor blood pressure: watch for hypotension, especially during initiation. - Monitor cardiac rhythm: observe for new or worsening arrhythmias. - Adjust dose in renal impairment: reduce infusion rate in patients with decreased clearance. - Use cautiously after recent myocardial infarction: assess risk of ischemia. - Avoid in severe aortic stenosis: may precipitate hemodynamic collapse. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Concomitant use with other PDE3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations, raising toxicity risk. - Potent vasodilators (e.g., nitroprusside): may produce profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Digoxin: combined effect on cardiac contractility requires ECG monitoring. - Diuretics and ACE inhibitors: monitor electrolytes and renal function.